Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
He says 'IMO' a lot. Do you think that adds gravitas to his post? Personally I don't think ramping or de-ramping work, as anybody stupid enough to base investment decisions on a BB deserves everything they get (or don't)
what I like about the cancer treating aspects is Avacta has recently had two strings to their bow.
The pre-cision technology, which basically build on well proven existing treatments but adds value by lowering the systemic toxic effects.
The use of affirmers to expose tumour cells to the bodies own immune systems.
Time scales are long, and it's a buy and hold. If you don't have time to wait, look elsewhere. It's a pretty binary proposition (although 2 strings to bow). If either works, current valuation will change overnight.
The covid test, its short term, but then allows the development of multiple test for other conditions. This is where current valuation lies, and CEO has stated as such.
Whilst the latest grab for more money was a little unexpected, company now has a position where they can add lots of strings to the bow. They only need one hit.
I didn't see anything wrong either, I appreciate views from all sides (unless they have an agenda). I agree with most of what alwayswinning says but I disagree slightly on the cancer treatement aspect. Whilst it may not add any meaningful value yet, it does have value and for me is the backstop for if coronavirus testing doesn't materialise as expected. Alastair still sees this as the key element for the company and has a lot of confidence in it
To be honest I didn’t see anything wrong in that post.
Those risks are there. But in relation to the return I think avacta represents a good investment. No share is without risk. The timescales are unknown for lots of things. If you have a different opinion just say why you differ, cos throwing names means people stop reading and opinion remains unchallenged.
No need to throw stones cos someone says try and find balance.
Might be a case of give a dog a bad name.
I would advise people to take seethree's advice and check my posting history. You'll note which companies I had reservations about while people were ramping them, and what's happened to them since.
If this thread was started by alwayslosing (I don't know as I have him filtered as he's a complete tool) then be influenced by him at your peril. Other than filtering may I also advise people look at his posting history. Basically he goes on to boards and shamelessly criticises everything about the stock, often spouting utter nonsense. He's done this on 5 other stocks recently. So, what can we take from this totally biased posting history? He is a paid, or self motivated shorter of stocks, his sole aim is to spread negativity in the hope that his short position is successful. He's clearly deluded and I imagine he's losing a hell of a lot of money as the AVCT price rises.....ahh poor little boy.
Nobody has corrected me. Please cite the sources as to where I've been deductively corrected.
Good lord you’re boring and relentless in your poor and obvious de-ramping efforts aren’t you?
Start a thread, talk rubbish, people correct you, start new thread. And repeat. Literally polluting the message board.
Is there a mute/block option on here??
So sell Your shares then mate if you have no confidence
I’ll take them off ya
Bye bye subtle de ramper
I just read the article posted by Malcolm Stacey and it pretty much echoes my feelings currently along with what TW said. It seems a fairly balanced and reasonable assessment of the current situation here.
The cancer treatment is too far down the road to add any meaningful value to the company yet, so anyone thinking they can fall back on that if the covid angle goes wrong needs their head feeling IMO.
About 80% of the current valuation being attributed by the market to this company is because of the LFT IMO. With every day Avacta doesn't deliver the test and get it to market the risk goes up in multiples IMO. I disagree with Tom on the matter of the virus simply dying out over a few months, but everything else I sort of agree with him on. For me the risk is, competition from other companies in the diagnostic space, and a vaccine being released a lot sooner than people expect. The potential profit gets smaller as the permutations grow extensive through competition and development elsewhere IMO.